博濟醫藥(300404.SZ):與惟楚醫療簽訂1.238億元的技術開發(委託)合同
格隆匯 10 月 12日丨博濟醫藥(300404.SZ)公佈,2020年10月10日,公司(“乙方”)與廣東惟楚醫療科技有限公司(“惟楚醫療”、“甲方”)簽訂了《技術開發(委託)合同》,合同總金額為人民幣12380萬元。
甲方作為化藥2.2類新藥“注射用鹽酸伊立替康(納米)膠束”臨牀試驗的申辦者,授權委託乙方進行該項目臨牀研究監查工作,並支付相應的臨牀研究經費,乙方接受委託並進行此項工作。
合同總金額為人民幣12380萬元,佔公司2019年度經審計的合併會計報表營業收入的55.25%,若此次合同能順利實施,將對公司未來經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.